Christophe Le Tourneau
Inserm(FR)Université de Versailles Saint-Quentin-en-Yvelines(FR)Université Paris-Saclay(FR)Institut des Neurosciences Paris-Saclay(FR)International Drug Development(FR)Institut Curie(FR)Institut Curie(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Peptidase Inhibition and Analysis
Most-Cited Works
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,656 cited
- → Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy(2014)1,342 cited
- → Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial(2015)1,100 cited
- → Dose Escalation Methods in Phase I Cancer Clinical Trials(2009)848 cited
- → Genomic characterization of metastatic breast cancers(2019)728 cited
- → Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma(2017)